tetano
Editor, Senior Moderator
Am J Emerg Med
. 2020 Jun 6;S0735-6757(20)30492-7.
doi: 10.1016/j.ajem.2020.05.117. Online ahead of print.
Toxic Shock-Like Syndrome and COVID-19: A Case Report of Multisystem Inflammatory Syndrome in Children (MIS-C)
Andrea G Greene[SUP] 1 [/SUP], Mona Saleh[SUP] 2 [/SUP], Eric Roseman[SUP] 3 [/SUP], Richard Sinert[SUP] 3 [/SUP]
Affiliations
Abstract
Early reports of COVID-19 in pediatric populations emphasized a mild course of disease with severe cases disproportionately affecting infant and comorbid pediatric patients. After the peak of the epidemic in New York City, in late April to early May, cases of severe illness associated with COVID-19 were reported among mostly previously healthy children ages 5-19. Many of these cases feature a toxic shock-like syndrome or Kawasaki-like syndrome in the setting of SARS-CoV-2 positive diagnostic testing and the CDC has termed this presentation Multisystem Inflammatory Syndrome (MIS-C). It is essential to disseminate information among the medical community regarding severe and atypical presentations of COVID-19 as prior knowledge can help communities with increasing caseloads prepare to quickly identify and treat these patients as they present in the emergency department. We describe a case of MIS-C in a child who presented to our Emergency Department (ED) twice and on the second visit was found to have signs of distributive shock, multi-organ injury and systemic inflammation associated with COVID-19. The case describes two ED visits by an 11- year-old SARS-CoV-2-positive female who initially presented with fever, rash and pharyngitis and returned within 48 hours with evidence of cardiac and renal dysfunction and fluid-refractory hypotension requiring vasopressors and PICU admission.
Keywords: COVID-19; Child; Coronavirus; Enoxaparin; Pediatric; Remdesivir; Septic; Shock; Tocilizumab.
. 2020 Jun 6;S0735-6757(20)30492-7.
doi: 10.1016/j.ajem.2020.05.117. Online ahead of print.
Toxic Shock-Like Syndrome and COVID-19: A Case Report of Multisystem Inflammatory Syndrome in Children (MIS-C)
Andrea G Greene[SUP] 1 [/SUP], Mona Saleh[SUP] 2 [/SUP], Eric Roseman[SUP] 3 [/SUP], Richard Sinert[SUP] 3 [/SUP]
Affiliations
- PMID: 32532619
- DOI: 10.1016/j.ajem.2020.05.117
Abstract
Early reports of COVID-19 in pediatric populations emphasized a mild course of disease with severe cases disproportionately affecting infant and comorbid pediatric patients. After the peak of the epidemic in New York City, in late April to early May, cases of severe illness associated with COVID-19 were reported among mostly previously healthy children ages 5-19. Many of these cases feature a toxic shock-like syndrome or Kawasaki-like syndrome in the setting of SARS-CoV-2 positive diagnostic testing and the CDC has termed this presentation Multisystem Inflammatory Syndrome (MIS-C). It is essential to disseminate information among the medical community regarding severe and atypical presentations of COVID-19 as prior knowledge can help communities with increasing caseloads prepare to quickly identify and treat these patients as they present in the emergency department. We describe a case of MIS-C in a child who presented to our Emergency Department (ED) twice and on the second visit was found to have signs of distributive shock, multi-organ injury and systemic inflammation associated with COVID-19. The case describes two ED visits by an 11- year-old SARS-CoV-2-positive female who initially presented with fever, rash and pharyngitis and returned within 48 hours with evidence of cardiac and renal dysfunction and fluid-refractory hypotension requiring vasopressors and PICU admission.
Keywords: COVID-19; Child; Coronavirus; Enoxaparin; Pediatric; Remdesivir; Septic; Shock; Tocilizumab.